Related references
Note: Only part of the references are listed.Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
K. Eto et al.
BRITISH JOURNAL OF CANCER (2013)
The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer
Beatrice Mohelnikova-Duchonova et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Advanced Cholangiocarcinoma Patients Treated With Gemcitabine-Based Adjuvant Chemotherapy After Surgical Resection
Hironori Kobayashi et al.
ANNALS OF SURGERY (2012)
Reduced Methylation of the Thromboxane Synthase Gene Is Correlated With Its Increased Vascular Expression in Preeclampsia
Ahmad A. Mousa et al.
HYPERTENSION (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
E. Martinez-Balibrea et al.
BRITISH JOURNAL OF CANCER (2010)
Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug Toxicity
Taro Okazaki et al.
CLINICAL CANCER RESEARCH (2010)
Mutations in SLC29A3, Encoding an Equilibrative Nucleoside Transporter ENT3, Cause a Familial Histiocytosis Syndrome (Faisalabad Histiocytosis) and Familial Rosai-Dorfman Disease
Neil V. Morgan et al.
PLOS GENETICS (2010)
Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3
Rajgopal Govindarajan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2009)
Association of polymorphisms in thromboxane A2 receptor and thromboxane A synthase 1 with cerebral infarction in a Korean population
Sun Ah Park et al.
BMB REPORTS (2009)
Common Polymorphisms in the Prostaglandin Pathway Genes and Their Association with Breast Cancer Susceptibility and Survival
Jean E. Abraham et al.
CLINICAL CANCER RESEARCH (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility
Hiroshi Hirata et al.
CANCER (2008)
Can me customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer
Rafael Rosell et al.
CLINICAL LUNG CANCER (2008)
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents
O. Moussa et al.
ONCOGENE (2008)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
V. Mey et al.
BRITISH JOURNAL OF CANCER (2006)
Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2
Hideki Sakai et al.
FEBS LETTERS (2006)
Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes
SA Baldwin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma
J Spratlin et al.
CLINICAL CANCER RESEARCH (2004)
Structure of a human carcinogen-converting enzyme, SULT1A1 - Structural and kinetic implications of substrate inhibition
NU Gamage et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Regulation of MCF-7 breast cancer cell growth by β-estradiol sulfation
JL Falany et al.
BREAST CANCER RESEARCH AND TREATMENT (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
